Specialty Dosage Drugs

Aug 01, 2017
Pharmaceutical Technology
Successful development requires coordinating and aligning drug and device design, focusing on a complete drug delivery system that meets patients’ needs.
Jul 21, 2017
By Pharmaceutical Technology Editors
The agency recommended a total of 11 drugs at its July meeting, including five orphan drugs.
Jul 05, 2017
By Pharmaceutical Technology Editors
ADV7103 is being evaluated in a Phase III trial in Europe in children and adults with distal renal tubulopathy acidosis. Results from the study are expected in the coming months.
Jul 05, 2017
By Pharmaceutical Technology Editors
SOBI003 is a chemically modified variant of a recombinant human sulfamidase product candidate, using Sobi’s proprietary glycan modification technology.
Jun 29, 2017
By Pharmaceutical Technology Editors
The agency announced a plan to eliminate its existing orphan designation request backlog.
Jun 13, 2017
Equipment and Processing Report
At an industry seminar hosted by Leistritz Extrusion, experts explained the use of extrusion equipment to mix polymeric excipients with APIs for solubility enhancement and for multifunctional and specialty dosage forms, including implants.
Jun 13, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Aptar now manufactures its child-resistant pump, designed to meet US CPC requirements, at its facility in Congers, New York.
Jun 02, 2017
Pharmaceutical Technology
Follow guidelines for E&L studies of an orally inhaled and nasal drug product formulation in its delivery device.
May 15, 2017
PTSM: Pharmaceutical Technology Sourcing and Management
By Pharmaceutical Technology Editors
Catalent has been working together with Lexicon to develop the drug formulation of Xermelo, which has now been approved by FDA for the treatment of carcinoid syndrome diarrhea.
Apr 25, 2017
Sponsored Content
Catalent combines its formulation expertise, manufacturing excellence and particle size reduction technologies to provide a broad range of solutions in the development of inhalation and nasal drug products.
native1_300x100
lorem ipsum